Skip to main content
Premium Trial:

Request an Annual Quote

New Products: University of Washington's UW-Onco-Plex; Sequenta's ClonoSight; LifeCodexx's PrenaTest


The University of Washington and Seattle Cancer Care Alliance have launched UW-Onco-Plex, a sequencing-based test to help guide treatment for cancer patients. The test uses the Illumina platform to analyze 194 genes associated with cancer. Doctors can order the test for their patients and turnaround time is approximately two months.

Sequenta has launched ClonoSight, its sequencing-based test to measure minimal residual disease in leukemia and lymphoma patients. The test is based on the company's proprietary LymphoSight technology, which targets unique DNA signatures that are present in immune cells. Its validation studies found that it could detect disease in as many as 10 percent of children with acute lymphoblastic leukemia that were found to be negative by flow cytometry.

GATC Biotech subsidiary LifeCodexx has launched an expanded version of its PrenaTest. The noninvasive, sequencing-based fetal aneuploidy test can now detect not only trisomy 21, but also trisomies 18 and 13.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.